Introduction The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. PGx testing represents a decision support tool that may inform dosing, increase the likelihood of treatment response, and identify patients at risk for medication side effects. Methods This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counselors, implementation scientists, industry, and clinicians. Results While many limitations exist to streamline use of PGx testing in psychiatry, various stakeholders are crucial to clinical implementation. Discussion PGx testing can assist in medication selection and improve patient outcomes; however, more data are needed to understand when and how to incorporate PGx testing into psychiatric practice.
Bibliographical noteFunding Information:
conflicts to declare. Dr. Susanne Haga has received research support from the National Institutes of Health (NIGMS). Dr. Je ? rey Strawn has received research support from the National Institutes of Health (NIMH, NIEHS, NICHD) as well as Allergan, Otsuka, Neuronetics and The Yung Family Foundation. He has received material support from and provided consultation to Myriad Genetics. Dr. Strawn also receives royalties from the publication of two texts (Springer) and serves as an author for UpToDate and an Associate Editor for Current Psychiatry. Dr. Heather Zeirhut receives research support from the National Society of Genetic Counselors. She is a Senior Advisor and Chair of the Advisory Board for GeneMatters, LLC, a tele-genetic counseling company.
© 2020 American Institute of Physics Inc.. All rights reserved.
PubMed: MeSH publication types
- Journal Article